Clinical Trial Update: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway [Phase 1]

View source ↗

Summary

Phase 1 trial of DCC-3084 for MAPK-pathway driven advanced cancers has been terminated. The update notes the study status without presenting efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• DCC-3084 (DCC-3084)

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Advanced Solid Tumor, RAF Mutation | Phase 1 | Status: TERMINATED